10-K - Ocugen, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Ocugen, Inc. reported a net loss of $67.8 million for fiscal year 2025, a significant increase from a $54.1 million loss in 2024. Total revenue was $4.4 million, derived from collaborative arrangements. The company's operating loss widened to $62.9 million, driven by increased research and development expenses of $39.8 million, primarily for clinical activities related to its lead gene therapy candidates OCU400, OCU410, and OCU410ST. General and administrative expenses were $27.6 million. The company ended the year with $18.6 million in cash and $39.5 million in cash and restricted cash, having used $57.0 million in operating activities. Management notes substantial doubt about the company's ability to continue as a going concern beyond the fourth quarter of 2026 without securing additional funding.

Key Takeaways

1Reported a net loss of $67.8 million for FY 2025, a 25% increase from the prior year.

2Research and development expenses increased by $7.6 million to $39.8 million, driven by clinical trial activities.

3Ended the year with $18.6 million in cash and a total cash position (including restricted cash) of $39.5 million.

4Cash used in operating activities was $57.0 million, primarily funding clinical development programs.

5Total liabilities were $55.7 million, exceeding total assets of $43.5 million, resulting in negative stockholders' equity of $12.2 million.

Key Financial Metrics

EPS

-$0

-$0 prior year

Revenue

$4.4M

+9%

Net Income

-$67.8M

-25%